Travere Therapeutics (NASDAQ:TVTX) Insider Jula Inrig Sells 6,956 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 6,956 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $32.12, for a total value of $223,426.72. Following the completion of the transaction, the insider directly owned 107,485 shares in the company, valued at approximately $3,452,418.20. This trade represents a 6.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Jula Inrig also recently made the following trade(s):

• On Tuesday, January 6th, Jula Inrig sold 445 shares of Travere Therapeutics stock. The stock was sold at an average price of $37.75, for a total transaction of $16,798.75.
• On Monday, January 5th, Jula Inrig sold 2,031 shares of Travere Therapeutics stock. The shares were sold at an average price of $40.18, for a total transaction of $81,605.58.
• On Wednesday, December 24th, Jula Inrig sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $630,000.00.

Travere Therapeutics Price Performance

TVTX stock opened at $32.84 on Wednesday. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23. Travere Therapeutics, Inc. has a 12-month low of $12.91 and a 12-month high of $42.13. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -30.98, a PEG ratio of 1.01 and a beta of 0.83. The firm’s 50-day moving average price is $34.11 and its two-hundred day moving average price is $27.76.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in shares of Travere Therapeutics in the 2nd quarter valued at about $33,000. First Horizon Corp purchased a new stake in shares of Travere Therapeutics in the third quarter valued at $36,000. Torren Management LLC acquired a new position in Travere Therapeutics in the fourth quarter valued at $38,000. Comerica Bank lifted its holdings in shares of Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after acquiring an additional 492 shares during the period. Finally, Garner Asset Management Corp acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at $69,000.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Wall Street Zen raised shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Guggenheim reaffirmed a “buy” rating and set a $49.00 target price on shares of Travere Therapeutics in a report on Wednesday, January 14th. Piper Sandler upped their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Zacks Research lowered shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Finally, Citigroup raised their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.86.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Negative Sentiment: Multiple senior insiders sold large blocks of shares on Feb 3, including CEO Eric M. Dube (100,087 shares, ~18.8% reduction in his position) and several executives (CFO, CAO and other officers) reducing holdings by ~5–10% each — a broad, same-day executive sell-off that can signal rotation or prompt investor concern about near-term insider confidence. CEO Form 4
• Negative Sentiment: A recent article questions Travere’s disclosure and risk narrative, flagging potential credibility concerns that could amplify selling or increase short-term volatility if investors seek more clarity from management. Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative?

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.